53 results about "Diseases outcome" patented technology

The present invention provides a method for diagnosing cancer, predicting a disease outcome or response to therapy in a patient sample. The method involves isolating a circulating tumor cell (CTC), for example, a viable CTC, from a sample using a parylene microfilter device comprising a membrane filter having or consisting of a parylene substrate, which has an array of holes with a predetermined shape and size; and detecting and quantifying telomerase activity in blood circulating tumor cells. The invention further provides methods of using cells live-captured in various applications.

Models for the systemic inflammatory response to infection, which involve the use of immunocompromised animals, and methods of using the models are described. These models can be used in identifying analytes or biomarker panels that can be used in staging or monitoring sepsis. The models can also be used for predicting an animal's disease outcome or in providing a prognosis for sepsis patients. Further, the invention relates to methods for evaluating potential treatments for sepsis.

A system and method for predicting disease outcome by analyzing a large, heterogeneous image by a boosted, multi-field-of-view (FOV) framework, based on image-based features from multi-parametric heterogeneous images, comprises (a) inputting the heterogeneous image; (b) generating a plurality of FOVs at a plurality of fixed FOV sizes, the method for generating the plurality of FOVs at a plurality of fixed FOV sizes comprising dividing simultaneously, via the computing device, the large, heterogeneous image into (i) a plurality of FOVs at a first fixed FOV size from among the plurality of fixed FOV sizes; and (ii) a plurality of FOVs at a second fixed FOV size from among the plurality of fixed FOV sizes; (c) producing simultaneously for the heterogeneous image a combined class decision for: (i) the plurality of FOVs at the first fixed FOV size, and (ii) the plurality of FOV s at the second fixed FOV size.

An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and / or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods.

The invention relates to the technical field of biomedical diagnostics and discloses a reagent kit for detecting a serum marker of primary hepatic carcinoma, which consists of an ELISA plate enveloped by antigens, an enzyme-labeled antibody working solution, a sample diluent, a washing liquid, positive and negative control serum, a chromogenic solution and a stopping liquid. The reagent kit is characterized in that the envelope antigens of the ELISA plate are five groups of peptide antigens L4-A and L4-B; L7-B; L11-1, L11-3 and L11-4; L12-A and L12-B; and Sui1-A and Sui1-B, which correspond to five serum marker antibodies of the primary hepatic carcinoma; and Sui1-A and Sui1-B respectively. Except the L7B which is separately enveloped, each group of all the other groups of peptide antigens is enveloped by proportionally mixing polypeptides in the same group. Proven by evaluation experiments of the reagent kit and clinical trial, the reagent kit has good specificity and sensitivity, and can be used for early warning prompt or early diagnosis before the primary hepatic carcinoma appears or at early stage of the primary hepatic carcinoma, thereby improving the survival rate of carcinoma patients and evaluating treatment effect and disease outcome in time by observing the dynamic change of related indicators of the serum.

The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising:(a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP(b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the invention provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying said patient into a high risk or a low risk category, based on a 92 gene classifier.

The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer.

The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of Akt1, Akt2, and Akt3. The methods and kits also allow prediction of disease outcome and staging of patients with regard to therapy.

Disclosed are systems and methods for predicting patient response to a treatment option. In one embodiment, the image slides from patient tissue samples are divided into patches and morphological patterns correlated with a disease outcome are labeled and given a patch-level score, based on whether the morphological patterns occur only in patients with good outcomes or patients with poor outcomes. A patient-level score can be generated based, at least partly, on the patch-level scores. Patch-level scores can identify regions of interest for targeted biomarker identification.

The present invention relates to the detection of field cancerization by detection of aberrations in tumor target genes at the margins of resected tumors, and the use of such information to predict survival in cancer patients. Methods for treatment of cancer based thereon also are provided.

A computer implemented method and a system choosing optimal disease treatment among several possible treatment options for a patient are provided. The system computes cancer-free survival rates for each considered treatment based on predicting recurrence rate of a disease and / or cancer outcome for a particular patient. The treatment survival models use quantitative data from histopathological images of the patient, clinical data and other patient information. The system segments the histopathological images into biologically meaningful components; automatically determines disease-affected regions in one or more of the segmented image components. The system also partitions the disease-affected regions in each image into a number clusters. Those that are determined to be the most associated with the disease outcome are used as a source of the imaging information for the survival modeling. Optimal treatment is suggested as the treatment with probability of the cancer free survival within a certain time period is maximized.

The invention relates to a model for evaluating gastric cancer prognosis based on Lauren typing and postoperative residual lymph nodes and application, and belongs to the technical field of biomedical detection. According to the invention, the number of residual lymph nodes after Lauren typing and neoadjuvant chemotherapy is comprehensively used as a prognosis evaluation index after neoadjuvant chemotherapy of gastric cancer, and a prognosis evaluation model for patients after neoadjuvant chemotherapy of gastric cancer is established. Through clinical verification, the evaluation model can effectively pre-judge disease outcome after neoadjuvant chemotherapy of gastric cancer, and is more accurate than the traditional Japan JGCA standard and German Becker standard. The invention provides reference information for prognosis of tumor patients, so that clinical doctors are helped to formulate the most reasonable diagnosis and treatment plan for the tumor patients, and timely and effective doctor-patient communication is facilitated.

Methods of preparing monoclonal antibodies that differentially bind to a single conformer of a protein of interest are described. Passive immunization using these antibodies as well as use of conformer-specific antibodies as diagnostic reagents for the purpose of stratification of patient populations with regards to disease outcome, drug efficacy or drug sensitivity is also disclosed as well as active immunization with the protein conformer. In the screening techniques, detection can be for example by tissue immunostaining, western blotting or solution IP. A specific mab termed 7VC which shows conformation specificity to CtmPrP, a prion protein conformer that triggers neurodegeneration under specific assay conditions of pH and copper concentration, is described. A second specific antibody termed 19B10 shows conformation specificity for NtmPrP, a prion protein conformer that downregulates total PrP expression and effects cell differentiation.

The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising:(a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP(b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

The invention belongs to the field of analytical chemistry and clinical medicine and relates to a plasma metabolization micromolecule marker related to the human non-small-cell lung cancer and an application of the plasma metabolization micromolecule marker. The plasma metabolization micromolecule marker related to the human non-small-cell lung cancer is one or more of cortisol, corticosterone and 4-methoxyphenylacetic acid. The plasma metabolization micromolecule marker is prepared from cortisol, corticosterone and 4-methoxyphenylacetic acid. The content range (95% confidence interval) of cortisol is 0.00018-0.00067, the content range (95% confidence interval) of corticosterone is 0.000029-0.00010, the content range (95% confidence interval) of 4-methoxyphenylacetic acid is 0.000015-0.000022, and metabolite can prompt occurrence of tumors within the ranges. The horizontal range, corresponding to a normal group, of cortisol is 0.0030-0.0037, the horizontal range, corresponding to the normal group, of corticosterone is 0.00044-0.00056, and the horizontal range, corresponding to the normal group, of 4-methoxyphenylacetic acid is 7.39 E-07-2.09 E-06. The plasma metabolization micromolecule marker is a novel biomarker, compared with a traditional protein biomarker, the relevance between the marker and the disease outcome is higher, and the plasma metabolization micromolecule marker is stable, minimally invasive, easy to detect and accurate in quantitation.

The invention discloses a suite reagent for titrating the titer of an EV71IgM antibody and an EV71IgG antibody of a hand-foot-mouth disease patient, comprising an ELISA (Enzyme Linked Immuno Sorbent Assay) plate and a detection reagent. The ELISA plate of the EV71IgM antibody comprises a polystyrene board, 1gM capture antibody is coated in polystyrene board holes, the ELISA plate of the EV71IgG antibody comprises a polystyrene board, and 1gM capture antibody is coated in the polystyrene board holes, and the detection reagent is EV71VP1 labeled by HRP (Horseradish Peroxidase). The suite reagent of the invention can be used for detecting the antibody titer of the hand-foot-mouth disease patient, the detection result can be used as a judgment result for judging disease outcome so that a clinical severe case can be predicted, prevented and controlled to lessen the probability of death cases.

The present invention describes clinically and medically important methods of monitoring the outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and / or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2 / neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2 / neu relative to control levels indicates poor outcome and short time to progression.

The present invention discloses a compound long-acting injection containing enrofloxacin and meloxicam. The compound long-acting injection comprises the enrofloxacin and / or a salt thereof, the meloxicam in a dispersion form, a meloxicam solid dispersoid, a high molecular retardant, a wetting agent and a dispersion medium; each 1,000 mL of the injection contains 20-250 g of the enrofloxacin and / orthe salt thereof (calculated by the enrofloxacin), 5-50 g of the meloxicam in the dispersion form, 5-30 g of the high molecular retardant, 5-20 g of the wetting agent, and the balance of a dispersionmedium; and a mass ratio of the meloxicam in the dispersion form to the meloxicam solid dispersoid (calculated by the meloxicam) is (5:1)-(1:1). The injection preparation is stable in quality, slow indrug release, safe and effective, only 1-2 times of drug administration in one course of treatment can treat both symptoms and root causes, and effective blood drug concentration is maintained for 3-7 days; and only 1 needle is used for injection for 1 time, so that the compound long-acting injection enhances animal compliance, reduces animal stress and is more favorable for disease outcome and prognosis.

The methods and compositions described herein address the need for a diagnostic method that can be provided to patients with early stage lung cancer, especially non-small cell lung cancer (NSCLC), to determine whether the patient is at increased risk of poor disease outcome. The methods and compositions thus allow for more informed treatment decisions for the early stage lung cancer patient.

The present invention relates to the field of Clostridium difficile infections. Methods of diagnosing, treating and preventing Clostridium difficile-associated disease and recurrent CDAD are disclosed herein.

Ovarian, cervical cancer, endometriosis, clear cell renal carcinoma cancers are very heterogeneous diseases which lack robust diagnostic, prognostic and predictive clinical biomarkers. Conventional clinical biomarkers (stages, grades, tumor mass etc) and molecular biomarkers (CA125, KRAS, p53 etc) are not appropriate for early diagnostics, differential diagnostics, prediction and prognosis of the disease outcome for individual patients. The most common type of the human ovarian cancers is human epithelial ovarian cancer (EOC). This cancer is characterized with one of the lowest survival rates compared to other cancers. The present invention relates to an in vitro method for diagnosing epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and / or predisposition to epithelial ovarian cancer in a subject, the method comprising determining in a sample of the subject gene expression level of at least one gene in the MDS1 and EVI1 complex (MECOM) locus; and / or copy number of at least one gene in the MECOM locus; wherein the level against at least one expression cutoff value and / or copy number against at least one copy number cutoff value are indicative of the subject having epithelial ovarian cancer, cervical cancer, endometriosis, clear cell renal carcinoma and / or a predisposition to epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and / or determining whether the ovarian cancer in the subject is primary or secondary ovarian cancer and / or a risk of the disease progression after surgery treatment, and / or an effectiveness of post-surgery chemotherapy.

The invention provides a novel DMPK isoform, isolated and purified RNA encoding the novel isoform, and methods of detecting the novel isoform, e.g., to predict disease outcome or detect disease.

The invention discloses a diffuse large B-cell lymphoma prognosis model based on MYC / BCL2 double expression and an immune microenvironment, application and a prognosis method. Based on the MYC / BCL2 protein expression level and the immune microenvironment, the MYC / BCL2 protein expression level and the immune microenvironment synergistically play a unique role in prognosis of various DLBCL subtype patients, assist clinicians in judging clinical development and disease outcome of the patients, and realize precise layered treatment.

The invention discloses the application of TWEAK in the preparation of lupus erythematosus diagnostic reagents, and belongs to the technical field of biomedicine. The present invention studies the role of serum and urine TWEAK levels in the diagnosis of different types of lupus erythematosus, and evaluates the relationship between TWEAK and SLE disease activity index (SLEDAI), so as to clarify its role in the process of disease diagnosis and monitoring, and in the The guiding role of glucocorticoid dosage, reduction and disease outcome in SLE treatment.